New insulin shows promise for type 1 diabetes in chinese trial

NCT ID NCT07282054

Completed Disease control Sponsor: Tonghua Dongbao Pharmaceutical Co.,Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tested a new fast-acting insulin called THDB0206 against a standard insulin (lispro) in 550 Chinese adults with type 1 diabetes. Both groups also used a long-acting insulin (glargine). The main goal was to see if THDB0206 could control blood sugar (HbA1c) as well as the standard treatment over 26 weeks. The study is complete, but results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: THDB0206 (a fast-acting insulin)
What this could lead to: If it works, this could offer a new fast-acting insulin option for people with type 1 diabetes, potentially improving blood sugar control.
What could go wrong: This is a completed Phase 3 trial, but results are not yet published. It only included Chinese adults, so findings may not apply to other populations. As with any insulin, risks include low blood sugar and injection site reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 1 DIABETES

Contacts and locations

Locations

Nanjing Drum Tower hospital

Nanjing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.